Abbott India names Anushree Kunhambu as Associate Director - New Product Introduction and Therapy Area Strategy
Mumbai: Abbott India has announced the appointment of Anushree Kunhambu as Associate Director - New Product Introduction and Therapy Area Strategy, effective August 1, 2025. She will be part of the Senior Management team of the Company.
The appointment follows the resignation of Namita Shah, who held the same position and stepped down from the company effective the close of business hours on April 15, 2025, as earlier reported by Medical Dialogues.
Anushree Kunhambu brings over a decade of experience in business development, licensing, and strategy across leading healthcare organizations. She joined Abbott in April 2021 as Head – Strategy & Portfolio, EPD India, where she led multiple high-impact licensing and acquisition deals across key therapy areas including biosimilars, gastrointestinal, women’s health, and CNS. Her strategic leadership played a pivotal role in driving both top-line and bottom-line growth, expanding the portfolio, and strengthening market competitiveness.
Headquartered in Mumbai, Abbott India Limited, a publicly listed company and a subsidiary of Abbott Laboratories The Company offers medicines in multiple therapeutic categories such as women's health, gastroenterology, cardiology, metabolic disorders and primary care.
Abbott India Limited is part of Abbott's global pharmaceutical business in India.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.